Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy.

Duffield AS, Ascierto ML, Anders RA, Taube JM, Meeker AK, Chen S, McMiller TL, Phillips NA, Xu H, Ogurtsova A, Berger AE, Pardoll DM, Topalian SL, Ambinder RF.

Blood Adv. 2017 Jul 21;1(17):1324-1334. doi: 10.1182/bloodadvances.2017007260. eCollection 2017 Jul 25.

2.

Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.

Yanik EL, Kaunitz GJ, Cottrell TR, Succaria F, McMiller TL, Ascierto ML, Esandrio J, Xu H, Ogurtsova A, Cornish T, Lipson EJ, Topalian SL, Engels EA, Taube JM.

JAMA Oncol. 2017 Jul 1;3(7):974-978. doi: 10.1001/jamaoncol.2017.0115.

3.

Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy.

Ascierto ML, Makohon-Moore A, Lipson EJ, Taube JM, McMiller TL, Berger AE, Fan J, Kaunitz GJ, Cottrell TR, Kohutek ZA, Favorov A, Makarov V, Riaz N, Chan TA, Cope L, Hruban RH, Pardoll DM, Taylor BS, Solit DB, Iacobuzio-Donahue CA, Topalian SL.

Clin Cancer Res. 2017 Jun 15;23(12):3168-3180. doi: 10.1158/1078-0432.CCR-17-0270. Epub 2017 Feb 13.

4.

The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma.

Ascierto ML, McMiller TL, Berger AE, Danilova L, Anders RA, Netto GJ, Xu H, Pritchard TS, Fan J, Cheadle C, Cope L, Drake CG, Pardoll DM, Taube JM, Topalian SL.

Cancer Immunol Res. 2016 Sep 2;4(9):726-33. doi: 10.1158/2326-6066.CIR-16-0072. Epub 2016 Aug 4.

5.

Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting.

Lipson EJ, Sharfman WH, Chen S, McMiller TL, Pritchard TS, Salas JT, Sartorius-Mergenthaler S, Freed I, Ravi S, Wang H, Luber B, Sproul JD, Taube JM, Pardoll DM, Topalian SL.

J Transl Med. 2015 Jul 5;13:214. doi: 10.1186/s12967-015-0572-3.

6.

Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade.

Taube JM, Young GD, McMiller TL, Chen S, Salas JT, Pritchard TS, Xu H, Meeker AK, Fan J, Cheadle C, Berger AE, Pardoll DM, Topalian SL.

Clin Cancer Res. 2015 Sep 1;21(17):3969-76. doi: 10.1158/1078-0432.CCR-15-0244. Epub 2015 May 5.

7.

Structure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicity.

Chen S, Li Y, Depontieu FR, McMiller TL, English AM, Shabanowitz J, Kos F, Sidney J, Sette A, Rosenberg SA, Hunt DF, Mariuzza RA, Topalian SL.

J Immunol. 2013 Nov 15;191(10):5097-106. doi: 10.4049/jimmunol.1300467. Epub 2013 Oct 9.

8.

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M.

N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.

9.

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.

Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, Chen L.

Sci Transl Med. 2012 Mar 28;4(127):127ra37. doi: 10.1126/scitranslmed.3003689.

10.

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL.

J Clin Oncol. 2010 Jul 1;28(19):3167-75. doi: 10.1200/JCO.2009.26.7609. Epub 2010 Jun 1.

11.

Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy.

Depontieu FR, Qian J, Zarling AL, McMiller TL, Salay TM, Norris A, English AM, Shabanowitz J, Engelhard VH, Hunt DF, Topalian SL.

Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12073-8. doi: 10.1073/pnas.0903852106. Epub 2009 Jul 6.

12.

Molecular characterization of the Caenorhabditis elegans REF-1 family member, hlh-29/hlh-28.

McMiller TL, Sims D, Lee T, Williams T, Johnson CM.

Biochim Biophys Acta. 2007 Jan;1769(1):5-19. Epub 2006 Dec 29.

PMID:
17258327
13.

Supplemental Content

Loading ...
Support Center